Benjamin Ebert assumed the role of CEO at the Dana-Farber Cancer Institute during a pivotal moment in late 2024. He is leading the organization at a time when it is engaged in constructing a significant $1.6 billion cancer hospital and is transitioning from its collaboration with Brigham and Women’s Hospital to establish a partnership with Beth Israel Lahey Health.
The groundwork for these changes was laid by his predecessor, Laurie Glimcher, who was at the helm of Dana-Farber from 2016 to 2024. Ebert, a medical oncologist who has held the position of chair of the department of medical oncology at the institute for seven years, brings a wealth of ideas and vision for the future of Dana-Farber. He recently shared these insights with the Globe. The conversation has been edited for brevity and clarity.
You’ve embarked on this significant project initiated by your predecessor. While progress is being made, there appears to be a substantial amount of work ahead.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
.
